Meningococcal B Outbreak on Campus: Are College Students Protected?
"Explore the effectiveness of mass vaccination clinics and what universities can do to better protect students."
Between January and May 2015, a somber reality unfolded at a large public university: seven individuals contracted invasive serogroup B meningococcal disease, with one case proving fatal. This outbreak, as detailed in a research article in the Journal of Adolescent Health, underscored a critical public health challenge, particularly among college students.
The university responded with mass vaccination clinics, deploying a newly licensed serogroup B vaccine in March, May, and October 2015. Yet, the study evaluating these clinics reveals a mixed bag of results, shedding light on the complexities of outbreak response and vaccination strategies in a university setting.
This article examines the findings of the original study, focusing on the vaccination rates, the demographics of those vaccinated, the preferred methods of communication, and the motivations driving students to get vaccinated. It further discusses the implications of these findings for future outbreaks, emphasizing the need for targeted strategies to protect those most vulnerable.
Coverage Gaps and Updated Bexsero Schedule
In a university-based mass immunization program responding to a meningococcal B outbreak, about 20% of individuals lacked vaccine coverage because of factors including no health insurance, lapsed eligibility, requirements for provider-administered vaccination, or insurance plans without a pharmacy benefit. Separately, in August 2024 the FDA changed Bexsero’s MenB-4C schedule from two doses at 0 and at least 1 month to two doses at 0 and 6 months, and added a three-dose schedule at 0, 1–2, and 6 months based on new immunogenicity data. These reports highlight both practical access barriers and a change in the recommended product schedule; the supplied material does not provide current case counts.
MenB Vaccination and Campus Prevention
Vaccines against meningococcal serogroups A, C, W, and Y have been recommended for U.S. adolescents since 2005, while the first U.S. MenB vaccine was approved in October 2014. Meningococcal infections occur sporadically as well as in outbreaks, and ten serogroup B outbreaks occurred on American college campuses between 2013 and 2018. A 2025 review suggests information campaigns about meningococcal disease and vaccination, especially at colleges and in states without vaccination requirements, as a potentially beneficial prevention strategy.
From Disease Recognition to Campus Outbreaks
The History of Vaccines describes Neisseria meningitidis as a cause of bacterial meningitis and sepsis in the United States, while noting that it can also cause pneumonia, ear infections, arthritis, and other less common infections. It reports that 10–20% of adolescents and adults may carry the bacteria without becoming ill, potentially for weeks or months, and that transmission can occur through direct contact such as kissing or respiratory secretions. A 2016 review argued that recent serogroup B outbreaks on college campuses warranted broader age-based MenB vaccine recommendations, similar to those for the quadrivalent vaccine against serogroups A, C, W, and Y.
Low Vaccination Rates: A Cause for Concern?
The study highlighted a concerningly low vaccination rate among undergraduates. Only 15% received one dose of the vaccine, and an additional 11% completed two doses of the three-dose MenB-FHbp series at the mass vaccination clinics. This means that a significant portion of the student body remained vulnerable despite the university's efforts.
- Preferred communication method: E-mail was the preferred method for receiving information about the vaccination clinics, cited by 90% of attendees.
- Motivations for attending: Concerns about contracting meningococcal disease (66%) and parental requests (56%) were the primary drivers for vaccination.
- Vaccine series completion: Only 4% of the undergraduate student body completed the serogroup B meningococcal vaccine series at a mass vaccination clinic.
Uptake, Campaign Evaluation, and Outbreak Guidance
A systematic review and meta-analysis of meningococcal vaccine uptake found that cost as a barrier could not be assessed in studies from countries without universal health coverage because of insufficient data, although cost is reported as an important barrier for other immunizations. The review also noted that first-year undergraduates may be more likely to vaccinate because they more often live on campus, have more recent contact with health services, or are more influenced by parents. A scoping review found that some college vaccination-campaign evaluations assessed student knowledge and attitudes, as well as reasons for vaccine reluctance. CDC’s account of U.S. university-based MenB outbreaks from 2013–2018 says it revised guidance for evaluating and managing suspected meningococcal outbreaks in 2017, partly in light of those outbreak experiences.
Evidence Gaps Around Protection and Boosters
A Canadian randomized trial report states that direct evidence had not been reported on how long a single dose of MenB-4C protects individuals in this age group against invasive meningococcal disease. CDC’s ACIP evidence review rates the overall certainty of evidence for the effectiveness and safety of MenB booster doses in people at increased risk during a serogroup B outbreak as very low. These limitations caution against treating either single-dose protection duration or outbreak booster effects as firmly established by the supplied evidence. A U.S. review describes adolescents and young adults ages 16–23 as having high rates of serogroup B meningococcal infections, with elevated risk among those attending college.
Different Outbreak-Strain Antibody Findings
In one university outbreak study, 1.5–2 months after immunization, 93% of vaccinated students (95% CI, 87%–97%) had protective titers of at least 1:4 against a campus outbreak isolate, compared with 37% of unvaccinated students (95% CI, 24%–51%). A separate study of 499 participants who received two doses of 4CMenB 10 weeks apart found that 66.1% were seropositive for the outbreak strain (95% CI, 61.8–70.3), with a geometric mean titer of 7.6 (95% CI, 6.7–8.5). These results describe different study findings and measures, so they should not be read as directly comparable estimates.
Looking Ahead: Enhancing Future Vaccination Strategies
The serogroup B meningococcal outbreak at the Oregon university provides valuable lessons for future public health responses on college campuses. While mass vaccination clinics can play a role, a more targeted approach focusing on high-risk groups is crucial. By refining communication strategies, addressing concerns, and ensuring accessibility, universities can strive for higher vaccination rates and better protect their students from this potentially devastating disease.
College Risk and State-Level Policy
A review of college meningococcal vaccination in the United States describes adolescents and young adults ages 16–23 as having high rates of serogroup B meningococcal infections, with elevated risk for those attending college. It examines vaccination requirements and recommendations for college students, with a focus on state-level mandates. The supplied summary does not specify which states have mandates or quantify their effects.
Unpredictable Outbreaks and Potential Consequences
A 2021 non-systematic review of literature published from 1997 to 2020 characterizes invasive meningococcal disease outbreaks as unpredictable, potentially sudden, and devastating. It reports that outbreaks involving serogroups A, B, C, W, Y, and X have occurred globally since 1997, and that the review assessed outbreak-response strategies and vaccine-intervention impacts. A separate 2020 study set out to examine how universal pre-enrollment vaccination might affect MenB outbreak probability and cost-effectiveness in outbreak-only scenarios, citing debilitating sequelae and substantial health-care use as concerns; the supplied summary does not report its results.